Skip to main content
Clinical Trials/NCT02111629
NCT02111629CompletedPhase 3

Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia.

Universidad Nacional de Colombia1 site in 1 country118 target enrollmentStarted: May 2012Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
118
Locations
1
Primary Endpoint
Effectiveness of treatment

Study Overview

Brief Summary

Genital tract infections (GTIs) have increased in the past decade and there is an association between sexually transmitted infections (STIs) and other infections like bacterial vaginosis (BV), with the HIV transmission. BV and Candida are the most common causes of vaginal infections in symptomatic women, the prevalence of BV being 22-50% and the prevalence of Candida 17-39%. In an effort to reduce the transmission of GTIs, the World Health Organization (WHO) proposed a syndromic diagnostic approach as a low cost alternative in places with no access to laboratory diagnostic tests.

Justification. In patients with syndrome of vaginal discharge, an effective treatment against Candida albicans, Trichomonas vaginalis, and bacterial vaginosis is adviced, therefore, for syndromic management of symptomatic vaginal discharge the combination of fluconazole and secnidazole could be used. No studies evaluating this combination were found in the literature reviewed.

Objectives: To describe the safety and the clinical and microbiological efficacy of a single oral dose of a combined treatment with secnidazole + fluconazole for the syndromic management of symptomatic vaginal discharge.

Methods: Design: open label, uncontrolled clinical trial to estimate clinical efficacy and safety of the combination of fluconazole and secnidazole for the treatment of symptomatic vaginal discharge. The participants will be sexually active women with lower genital tract symptoms (leukorrhea, itching, burning, pain, foul-smelling vaginal discharge, or urethral symptoms) compatible with symptomatic vaginal discharge syndrome. The study will be conducted in an outpatient service of a hospital in Bogota, Colombia. Given the descriptive character of the study, no a priori hypothesis is considered. A consecutive convenience sample size of 100 symptomatic patients is calculated. The statistical analysis will be performed with STATA 11.0 software (College Station, Texas, USA). Simple and relative frequencies and measures of central tendency and dispersion appropriate for the distribution of the variables will be calculated. The study has been submitted and approved by the Ethics Committee of the Faculty of Medicine of the National University of Colombia and the Institutional Review Board of the participating institution. All women must sign a written informed consent form agreeing to voluntarily participate in the study.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • sexually active women with lower genital tract symptoms compatible with BV or vaginitis

Exclusion Criteria

  • patients with a clinical diagnosis of cervicitis
  • severe medical conditions
  • liver disease
  • allergies, or known reactions to the drugs under study were excluded from the study
  • pregnant women
  • women who were not yet sexually active
  • women who had previously participated in the study
  • women who had received antibiotic therapy in the previous 14 days

Arms & Interventions

Fluconazole and Secnidazole

Experimental

Intervention: Fluconazole and Secnidazole (Drug)

Outcomes

Primary Outcomes

Effectiveness of treatment

Time Frame: Participants will be followed an expected average of 10 weeks

Clinical cure and microbiological cure rates, and the cure rate for diagnostic subgroups

Secondary Outcomes

  • Safety(Up to 10 Weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South AfricaUreaplasma Urealyticum InfectionMycoplasma Genitalium InfectionSexually Transmitted Infections (Not HIV or Hepatitis)Microbial ColonizationChlamydia Trachomatis InfectionNeisseria Gonorrheae InfectionTrichomonas VaginitisVaginal CandidaGenital Mycoplasma InfectionInfection PregnancyBacterial VaginosisHIV InfectionsPremature Birth
NCT06131749University of Bern603
Not yet recruiting
Not Applicable
Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General PopulationHIV Infections
NCT05983679CerbaXpert9,000
Unknown
Not Applicable
Partner Notification of Sexually Transmitted Infections (STIs) in Testing CentersSTIHiv
NCT04921618ANRS, Emerging Infectious Diseases2,200
Completed
Unknown
Knowledge, attitudes and practices of primary care professionals on sexual behavior and sexually transmitted infections in the elderly: a quasi-experimental studysexually transmitted diseases, sexuality, agedN04.590.233.727
RBR-5q5z486niversidade do Estado de Mato Grosso
Completed
Not Applicable
Occurrence of genitourinary infections and describing the epidemiological profile of pregnant teenagers at the Intituto de Saude Elpidio de Almeida - ISEA in Campina Grande, Paraiba, BrazilThis study addresses the presence of urinary or vaginal infections in pregnant women in Brazilian public institution.Epidemioly of public health in Campina Grande in Paraiba.Infection - Other infectious diseasesPublic Health - Epidemiology
ACTRN12610000960055niversidade Estadual da Paraiba92